Odyssey Therapeutics Inc. (ODTX) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $19.83 (+1.48% 1D, market cap $953.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ODTX ranks #215 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRME (Prime Medicine Inc.) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M) and MGTX (MeiraGTx Holdings plc) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $932.1M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while PRME leads on capital efficiency (-35.0% ROIC).
Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 34% of 52W Range • RSI-14 at 48.9 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 59/100 (C-) score, ODTX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.79) or 200D SMA ($19.71) invalidates the momentum regime and cuts Target Base ($19.92) toward Bear Floor ($15.54).
Odyssey Therapeutics Inc. (ODTX) advanced +1.48% to $19.83, trading at 34% of its 52-week range ($15.1 – $29.05). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation October 20, 2026 8:00 AM...
Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001 Favor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ODTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ODTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Odyssey Therapeutics Inc. (ODTX) ranks #215 by composite RQD confidence (59/100, grade C-) and #365 by equity capitalization ($953.0M). Within this direct 5-issuer industry benchmark cohort, ODTX leads on earnings valuation at N/A trailing P/E, while PRME leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ODTX
ACTIVE
Odyssey Therapeutics Inc. | C- | 59/100 | — | — | — | +1.48% | $953.0M | Benchmark Subject |
| PRME Prime Medicine Inc. | E | 21/100 | — | — | -35.0% | -2.24% | $950.4M | /prme-vs-odtx → |
| MGTX MeiraGTx Holdings plc | E | 27/100 | — | — | -35.0% | -0.46% | $932.1M | /mgtx-vs-odtx → |
| GLUE Monte Rosa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +0.18% | $927.4M | /glue-vs-odtx → |
| CGEM Cullinan Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -0.71% | $994.3M | /cgem-vs-odtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Odyssey Therapeutics Inc. (ODTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ODTX closed FY2025 with $269.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $269.8M | — |
As of 2026-11-01, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $19.83 (+1.48% 1D, market cap $953.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ODTX ranks #215 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRME (Prime Medicine Inc.) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M) and MGTX (MeiraGTx Holdings plc) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $932.1M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while PRME leads on capital efficiency (-35.0% ROIC).
Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ODTX last traded at $19.83 (+1.48% on volume of 212,840 shares), positioning the stock -8.99% below its 50-day simple moving average ($21.79) and +0.61% above its 200-day simple moving average ($19.71). Across its 52-week range of $15.10 to $29.05, ODTX sits at the 33.9% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.35 to $22.31).
Why ODTX Stock advanced +1.48% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.